Skip to main content
Elsevier
View Cart
My account

Books in Drug discovery

Elsevier's Drug Delivery collection is an indispensable resource for scientists and researchers in the pharmaceutical field, exploring the administration of pharmaceutical compounds for therapeutic effects from molecule identification to medication development. It provides comprehensive coverage, including crucial aspects such as drug screening, medicinal chemistry, and preclinical safety assessments. Highlighting emerging trends like precision medicine, AI applications, immunotherapy, and innovative delivery systems, the collection offers insights into the latest advancements and their impact on healthcare.

BooksJournals

    • Animal and Translational Models for CNS Drug Discovery: Reward Deficit Disorders

      • 1st Edition
      • October 6, 2008
      • Robert A. McArthur + 1 more
      • English
      • Hardback
        9 7 8 0 1 2 3 7 3 8 6 0 8
      • Paperback
        9 7 8 0 1 2 4 0 5 4 9 3 6
      • eBook
        9 7 8 0 0 8 0 9 2 0 4 0 5
      Reward Deficit Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for reward deficit disorders such as alcohol dependence, nicotine dependence, heroin and cocaine addiction, obesity, and gambling and impulse control disorders. Reward Deficit Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. Reward Deficit Disorders also has a section dedicated to the specifics of the regulatory aspects to abuse liability testing. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the third volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, which is also available for purchase individually.

    • Animal and Translational Models for CNS Drug Discovery: Neurological Disorders

      • 1st Edition
      • October 6, 2008
      • Robert A. McArthur + 1 more
      • English
      • Paperback
        9 7 8 0 1 2 4 0 5 4 9 1 2
      • Hardback
        9 7 8 0 1 2 3 7 3 8 5 5 4
      • eBook
        9 7 8 0 0 8 0 9 2 0 3 8 2
      Neurological Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for neurological disorders such as neurofibromatosis, Alzheimer’s disease, Parkinson’s disease, Huntington disease, ALS, and the epilepsies. Neurological Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the second volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, which is also available for purchase individually.

    • Target Validation in Drug Discovery

      • 1st Edition
      • September 22, 2006
      • Brian W. Metcalf + 1 more
      • English
      • Hardback
        9 7 8 0 1 2 3 6 9 3 9 3 8
      • eBook
        9 7 8 0 0 8 0 4 6 5 9 7 5
      This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.

    • Advances in Cancer Research

      • 1st Edition
      • Volume 96
      • December 19, 2006
      • English
      • Hardback
        9 7 8 0 1 2 0 0 6 6 9 6 4
      • eBook
        9 7 8 0 0 8 0 4 7 1 0 1 3
      The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume stands as the first ever thematic volume in the series, focusing on the topic of genomics in cancer drug development. The chapters included in this book represent the cutting-edge information in the field and span such topics as Mass Spectrometry: Uncovering the Cancer Proteome for Diagnostics; Biomarker Discovery in Epithelial Ovarian Cancer by Genomic Approaches; The Application of siRNA Technology to Cancer Biology Discovery; Ribozyme Technology for Cancer Gene Target Identification and Validation; Cancer Cell-Based Genomic and Small Molecule Screens; Tumour Antigens as Surrogate Markers and Targets for Therapy and Vaccines; Practices and Pitfalls of Mouse Cancer Models in Drug Discovery; Biomarker Assay Translation from Discovery to Clinical Studies in Cancer Drug Development – Quantification of Emerging Protein Biomarkers; Molecular Optical Imaging of Therapeutic Targets of Cancer; Cancer Drug Approval in the United States, Europe and Japan.

    • Drug Discovery

      • 1st Edition
      • December 15, 2005
      • Tamas Bartfai + 1 more
      • English
      • Paperback
        9 7 8 0 1 2 3 6 9 5 3 3 8
      • eBook
        9 7 8 0 0 8 0 9 1 9 2 3 2
      Everyone expects something from the drug industry. Physicians and patients, investors, regulators and administrators all have an active interest. Everyone wants to know what makes drugs ‘work’ medically and economically. Why are drugs so expensive? Is it the drug companies or investors who demand high profits? What governs the pharmacoeconomics? Why are so few diseases treatable? Drug Discovery opens the windows and doors of the industry telling the story of drug development by using real stories from inside the process.

    • Ethnomedicine and Drug Discovery

      • 1st Edition
      • Volume 1
      • March 1, 2002
      • M.M. Iwu + 1 more
      • English
      • Paperback
        9 7 8 0 4 4 4 5 4 0 0 6 5
      • eBook
        9 7 8 0 0 8 0 5 3 1 2 5 0
      The emergence of new infectious, chronic and drug resistant diseases have prompted scientists to look towards medicinal plants as agents for treatment and prevention. This book provides an interphase between ethnomedical and ethnobotanical approaches to new drug discovery and advances in biotechnology and molecular science that has made it increasingly feasible to transform traditional medicines into modern drugs. These novel approaches also raise new issues and the volume explores economic, ethical and policy considerations of drug development based on indigenous knowledge or traditional medicine.This work also features standardization and development of phytomedicines for major therapeutic indications, including emerging infectious diseases affecting developing and developed countries.The publication provides state-of-the-art information on the most innovative science, the research, the industry, the market, and the future of ethnomedicine and drug discovery.

    • Trends in Drug Research III

      • 1st Edition
      • Volume 32
      • January 25, 2002
      • H. van der Goot
      • English
      • Paperback
        9 7 8 0 4 4 4 5 4 0 0 4 1
      • eBook
        9 7 8 0 0 8 0 5 4 3 2 3 9
      The tradition of setting new trends in medicinal chemistry continued at the 13th Symposium where topics included chemical and biological diversity, new paradigms in drug action, and new insights in receptor mechanisms. Other topics of great interest discussed, and included in these proceedings, are the discoveries in green chemistry, the interface between organic synthesis and biosynthesis, the growing problem of resistant micro-organisms and the possibilities to identify new, and better, antibiotics. And finally, in recent developments, the discovery of small molecules with insulin sensitizing properties.

    • Advances in Drug Research

      • 1st Edition
      • Volume 30
      • August 12, 1997
      • English
      This volume continues the trend for Advances in Drug Research of shorter, but more frequent volumes. In line with the tradition of the series, chapters on general themes are interspersed with chapters on specific drug classes and targets. It will be the last volume edited by Bernard Testa and Urs A. Meyer.